Notice of Effectiveness · EFFECT
Lexeo Therapeutics, Inc.
LXEONASDAQEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-11-04
- Effective time (as filed)
- 16:00:00
- Form
- S-3
Registrant 1
- Registrant
- Lexeo Therapeutics, Inc.
- Registrant CIK
- 0001907108
- File number
- 333-299689
Company context
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.